134 related articles for article (PubMed ID: 37864551)
1. Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
Hervochon C; Hennart B; Leroy AG; Corvec S; Boutoille D; Senneville É; Sotto A; Illes G; Chavanet P; Dubée V; Bleibtreu A; De Carné MC; Talarmin JP; Revest M; Castan B; Bellouard R; Dailly É; Allorge D; Dinh A; Le Turnier P; Gregoire M;
J Antimicrob Chemother; 2023 Dec; 78(12):2919-2925. PubMed ID: 37864551
[TBL] [Abstract][Full Text] [Related]
2. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
3. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intraosteoblastic activity of dalbavancin against Staphylococcus aureus in an ex vivo model of bone cell infection.
Chauvelot P; Dupieux-Chabert C; Abad L; Souche A; Ferry T; Josse J; Laurent F; Valour F;
J Antimicrob Chemother; 2021 Oct; 76(11):2863-2866. PubMed ID: 34423360
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients.
Carrothers TJ; Lagraauw HM; Lindbom L; Riccobene TA
Pediatr Infect Dis J; 2023 Feb; 42(2):99-105. PubMed ID: 36638392
[TBL] [Abstract][Full Text] [Related]
10. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.
Van Matre ET; Teitelbaum I; Kiser TH
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122898
[TBL] [Abstract][Full Text] [Related]
11. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
[TBL] [Abstract][Full Text] [Related]
12. Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization.
Zhang R; Polenakovik H; Barreras Beltran IA; Waalkes A; Salipante SJ; Xu L; Werth BJ
Clin Infect Dis; 2022 Oct; 75(9):1641-1644. PubMed ID: 35510938
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
[TBL] [Abstract][Full Text] [Related]
15. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
16. Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
Sivori F; Cavallo I; Kovacs D; Guembe M; Sperduti I; Truglio M; Pasqua M; Prignano G; Mastrofrancesco A; Toma L; Pimpinelli F; Morrone A; Ensoli F; Di Domenico EG
Microbiol Spectr; 2022 Apr; 10(2):e0035122. PubMed ID: 35416701
[TBL] [Abstract][Full Text] [Related]
17. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
18. Anti-biofilm activity of dalbavancin against methicillin-resistant
Silva V; Miranda C; Bezerra M; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
J Chemother; 2021 Nov; 33(7):469-475. PubMed ID: 33904369
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age.
Bradley JS; Puttagunta S; Rubino CM; Blumer JL; Dunne M; Sullivan JE
Pediatr Infect Dis J; 2015 Jul; 34(7):748-52. PubMed ID: 25551831
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.
Jabés D; Candiani G; Romanó G; Brunati C; Riva S; Cavaleri M
Antimicrob Agents Chemother; 2004 Apr; 48(4):1118-23. PubMed ID: 15047510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]